Oncovision 2026: Armed Forces Oncology Group Focuses on Multidisciplinary Care and Returning Cancer Survivors to Active Duty
NEW DELHI — July 04, 2026: The Armed Forces Oncology Group (AFOG) officially convened its annual meeting at the Army Hospital (Research & Referral) as part of “Oncovision 2026.” Under the progressive theme “Advancing the Frontlines – Strategic Innovations in Oncology,” senior oncology specialists and administrative leaders from across the Armed Forces Medical Services (AFMS) gathered to deliberate on critical advancements in military healthcare. The core discussions focused heavily on strengthening the existing multidisciplinary cancer care framework through Malignant Disease Treatment Centres (MDTCs) and fostering collaborative clinical research across service branches. Notably, a major focal point of the assembly was exploring the formal restoration of selected, deserving cancer survivors back to their normal medical categories following successful, curative treatments.
Underscoring this forward-thinking initiative, Director General of Armed Forces Medical Services (DGAFMS) Surg Vice Admiral Arti Sarin emphasized the profound importance of restoring eligible cancer survivors to normal medical standing, noting that successful treatment should open doors for personnel to resume full service duties. She further reaffirmed that the MDTC model continues to serve as the structural cornerstone of holistic, patient-centric, and multidisciplinary oncology care within the AFMS. The high-level annual meeting witnessed active participation from several top military medical minds, including Surg Vice Admiral KM Adhikari, Deputy Chief of Integrated Defence Staff (Medical), alongside other veteran specialists representing the fields of medical, surgical, and radiation oncology.